March 17, 2023 • by Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt
It is important to note that the adverse events (AEs) in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.
Key points in this report include:
- 69 patients, including one infant, suffered acute kidney injury or acute renal failure. The vaccine was not authorized for infants during this time.
- Pfizer’s renal adverse event reports screen only for the most severe damage but miss important, less severe kidney damage. Thus, Pfizer’s post-marketing kidney adverse events are likely significantly underreported.
- Half of the severe renal adverse events were reported within four days of vaccination.
- 67% of kidney adverse event patients were women, and 33% were men.
- The very short range of latency shows the severity of the damage in this SOC.
- Pfizer reported that surveillance would continue for this SOC, yet no information on subsequent surveillance has been publicly released to date… Read/download full report
